A Phase 1 Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, 2-cohort, fixed-sequence, DDI study in healthy
adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in
combination with midazolam or clarithromycin and assessed for safety and tolerability
including blood tests to show how the body metabolizes and eliminates the investigational
drug as well as how the investigational drug interacts with midazolam or clarithromycin.